DarDoc Research

GLP-1 Trial & Approval Tracker

Compare GLP-1 trial arms

Compare results within a trial or inspect the context behind results from different studies.

SYNCHRONIZE-1

Survodutide

Without diabetes · 76 weeks · n=726

Double-blind, placebo-controlled. Treatment-regimen estimand. The trial randomised 726 participants and analysed 725.

Mean body weight change at 76 weeks
  • Survodutide up to 3.6 mg−12.2%
  • Survodutide up to 6.0 mg−13.0%
  • Placebo−5.4%
Published paper PubMed abstract NCT06066515

A direct comparison uses arms from the same trial. Switch to Two studies to inspect the context behind separate results.